Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Conditions:   Metastatic Malignant Female Reproductive System Neoplasm;   Platinum-Resistant Malignant Female Reproductive System Neoplasm;   Recurrent Malignant Female Reproductive System Neoplasm;   Refractory Malignant Female Reproductive System Neoplasm Interventions:   Biological: Durvalumab;   Radiation: Internal Radiation Therapy;   Biological: Tremelimumab Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials